ES2101849T3 - Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma. - Google Patents

Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma.

Info

Publication number
ES2101849T3
ES2101849T3 ES92912541T ES92912541T ES2101849T3 ES 2101849 T3 ES2101849 T3 ES 2101849T3 ES 92912541 T ES92912541 T ES 92912541T ES 92912541 T ES92912541 T ES 92912541T ES 2101849 T3 ES2101849 T3 ES 2101849T3
Authority
ES
Spain
Prior art keywords
hepatocitos
gamma
growth
stimulation
interfered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912541T
Other languages
English (en)
Inventor
Paula M Jardieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2101849T3 publication Critical patent/ES2101849T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION ES RELATIVA A LA INTERACCION SINERGISTICA DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (HGF) Y DE GAMMA ERON (IFN GAMMA) EN LA ESTIMULACION DEL CRECIMIENTO DE HEPATOCITO. POR CONSIGUIENTE, LA INVENCION CONCIERNE A UN METODO DE MEJORAR LA ACTIVIDAD BIOLOGICA DE HGF ADMINISTRANDO UNA CANTIDAD BIOLOGICAMENTE EFECTIVA DE HGF Y UNA CANTIDAD SINERGISTICAMENTE EFECTIVA DE IFN GAMMA A UN PACIENTE QUE LO NECESITE.
ES92912541T 1991-06-10 1992-05-19 Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma. Expired - Lifetime ES2101849T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/712,284 US5227158A (en) 1991-06-10 1991-06-10 Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon

Publications (1)

Publication Number Publication Date
ES2101849T3 true ES2101849T3 (es) 1997-07-16

Family

ID=24861484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92912541T Expired - Lifetime ES2101849T3 (es) 1991-06-10 1992-05-19 Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma.

Country Status (12)

Country Link
US (1) US5227158A (es)
EP (1) EP0606210B1 (es)
JP (1) JPH06508148A (es)
AT (1) ATE151292T1 (es)
AU (1) AU655653B2 (es)
CA (1) CA2109434A1 (es)
DE (1) DE69218956T2 (es)
DK (1) DK0606210T3 (es)
ES (1) ES2101849T3 (es)
GR (1) GR3023613T3 (es)
WO (1) WO1992022321A1 (es)
ZA (1) ZA923980B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
WO1993023550A2 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5855918A (en) * 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
WO1997012629A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor
AU7389496A (en) * 1995-10-05 1997-04-28 Genentech Inc. Methods and compositions for treating vascular stenosis
CN1055517C (zh) * 1996-03-29 2000-08-16 唐禾天 叶片转子式发动机
US6280739B1 (en) 1996-04-18 2001-08-28 Genetics Institute, Inc. Method of inhibiting angiogenesis using secreted proteins
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
EP1351707B9 (en) * 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL165392A0 (en) * 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT1718677E (pt) * 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US20050244959A1 (en) * 2004-03-30 2005-11-03 Anne Corlu Methods for inducing active hepatocytes proliferation, kits using such methods and uses of said kits
LT1781698T (lt) * 2004-07-20 2016-09-26 Genentech, Inc. Į angiopoetiną panašaus baltymo 4 kompozicijos ir panaudojimo būdai
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8236761B2 (en) * 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
CA2716670A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
RU2720451C1 (ru) * 2019-05-06 2020-04-29 Анастасия Юрьевна Лаптиёва Способ стимуляции пострезекционной пролиферации гепатоцитов путем внутрипеченочного введения цианокобаламина

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0294160A1 (en) * 1987-06-02 1988-12-07 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US4973478A (en) * 1987-07-20 1990-11-27 Allelix Biopharmaceuticals, Inc. Treating inflammation with hepatocyte stimulating factor interferon β2
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
DK0606210T3 (da) 1997-05-05
ATE151292T1 (de) 1997-04-15
ZA923980B (en) 1993-12-01
CA2109434A1 (en) 1992-12-11
EP0606210B1 (en) 1997-04-09
JPH06508148A (ja) 1994-09-14
EP0606210A1 (en) 1994-07-20
US5227158A (en) 1993-07-13
AU2144192A (en) 1993-01-12
GR3023613T3 (en) 1997-08-29
DE69218956D1 (de) 1997-05-15
AU655653B2 (en) 1995-01-05
WO1992022321A1 (en) 1992-12-23
DE69218956T2 (de) 1997-07-31

Similar Documents

Publication Publication Date Title
ES2101849T3 (es) Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69433870D1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
MX9203294A (es) Factor de estimulacion de aniquilador natural.
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
MX169205B (es) Composicion para estimular el crecimiento del cabello
DE3583849D1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
SE9701161D0 (sv) New use I
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
DE3685484D1 (es)
IL102753A0 (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
ATE229981T1 (de) Glykolisierte cytokine
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
ZA873743B (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
ZA928105B (en) Treatment of anxiety in benzodiazpine-withdrawn patients
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
DE69005837D1 (de) Verwendung bestimmter gamma-Interferone zur Behandlung von Krebs des Ovars.
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
DK0671918T3 (da) Præparater indeholdende acyclovir-lignende forbindelser og 2-vinylsubstituerede nucleosidanaloge til behandling af virusinfektioner
ES2054207T3 (es) Metodos de uso de 2-isopropil-2-fenilaminovaleronitrilos como inmunosupresores y vasodilatadores.
NO911470D0 (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 606210

Country of ref document: ES